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population would smoke.6 During the 
programme, smoking and hospital 
admissions decreased and disease costs 
decreased.7
Sleep apnoea was hardly recognised 
in the 1980s but was common 
and often associated with other 
diseases, especially in people who 
were overweight. The results of the 
Sleep Apnoea Programme (2002–12) 
have been poorly documented, but 
improved awareness has generated 
care guidelines for clinicians.
In 2013, Filha took up the challenge 
of tackling tuberculosis again, 
especially drug resistance concerns 
and the increasing numbers of new 
cases among young immigrants. For 
primary care, chest X-ray was used to 
screen any suspected cases. As a result 
of these efforts, the situation has been 
stable, and the number of new cases 
has remained under 300 per year, and 
drug resistance has not become a 
substantial problem.
In the early 2000s, a stark contrast 
became apparent in allergic disorders, 
including asthma, between Finnish 
and Russian Karelia populations.8 It 
was best explained by changes in 
environment and lifestyle affecting 
microbiota and immune regulation. 
The Allergy Programme which ran 
from 2008 to 2018 endorsed both 
immune and psychological tolerance 
instead of avoidance. Allergy health 
was promoted and severe symptoms 
were prioritised. The mid-term 
results indicate a decrease in allergy 
diets, occupational allergies, asthma 
emergency visits, and halting the 
predicted cost increase.9
Respiratory health of the Finnish 
population has improved substan-
tially and benefited from innovative 
research and exceptionally long-term 
implementation strategies with the 
commitment of all stakeholders, 
includ ing health authorities and 
patient organisations. The Indoor Air 
Programme (2018–28) is the latest 
action to support modern citizens, 
who are increasingly living in urban 
environments and indoors.10 Distance 
25 years of respiratory 
health in Finland
The Finnish Asthma Programme 
was recently discussed in Spotlight 
in The Lancet Respiratory Medicine.1 
Indeed, it started a series of six 
Programmes improving respiratory 
health in Finland. The pioneering 
effort was, however, the one against 
tuberculosis, launched in 1893. 
Because of Mycobacterium tuberculosis, 
Finland (which had a population 
of less than 4 million) built a 
network of 17 Central Sanatoriums 
comprising about 5700 beds 
in 1945. An integrated care pathway 
was constructed from prevention 
(vaccination) to early detection (mass 
miniature X-ray), treatment with long-
term institutional and outpatient 
care, as well as rehabilitation and 
social support. In 1960s, other lung 
diseases started to gain attention as 
tuberculosis decreased.
Asthma emerged as a new kind of 
epidemic, and was still poorly treated 
in 1980s. When its inflammatory nature 
was recognised,2,3 treatment changes 
were implemented by Filha, the Finnish 
Lung Health Association (formerly 
known as the Anti-Tuberculosis 
Association), a professional body and 
non-govern mental organ isation. 
The Asthma Programme, which ran 
from 1994 to 2004, linked primary 
and secondary care,4 and with the 
help of WHO, also served as a model 
for countries of transition, such as 
Kyrgyzstan.5
The next focus for respiratory health 
was the so-called smokers’ disease, 
chronic obstructive pulmonary 
disease (COPD). The patients were 
elderly and often vulnerable, not able 
to speak for themselves. During the 
COPD Programme which ran from 
1998 to 2007, primary care personnel 
were trained to measure lung function 
for objective screening. Anti-smoking 
campaigns started and an endgame 
for smoking cessation by 2040 
(now 2030) was declared, implying 
that at that time less than 5% of the 
learning and multidisciplinary 
partici pation of both professionals 
and lay public are the focus of this 
programme.
At 102 years old, Filha is moving its 
focus from treatment to prevention, 
and using its experience to combat 
other non-communicable diseases.
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